Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2704-2709

  Willmann, Dominica ^a   Lim, Soyoung ^b   Wetzel, Stefan ^c   Metzger, Eric ^a   Jandausch, Anett ^a   Wilk, Wolfram ^c,g   Jung, Manfred ^d   Forne, Ignasi ^e   Imhof, Axel ^e   Janzer, Andreas ^f   Kirfel, Jutta ^f   Waldmann, Herbert ^c   Schüle, Roland ^a   Buettner, Reinhard ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

chromatin modifying enzyme; demethylation; inhibitor; LSD1; prostate cancer

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANDROGEN RECEPTOR; CLORGYLINE; HISTONE H3; LYSINE; LYSINE SPECIFIC DEMETHYLASE 1; NAMOLINE; OXYGENASE INHIBITOR; PARGYLINE; PYRONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE;

ANDROGENS; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHROMATIN; ENZYME INHIBITORS; HISTONE DEMETHYLASES; HISTONES; HUMANS; MALE; METHYLATION; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRONES; RECEPTORS, ANDROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867091498     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27555     Document Type: Article

References (20)

1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ,. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24.
2. Frydenberg M, Stricker PD, Kaye KW,. Prostate cancer diagnosis and management. Lancet 1997; 349: 1681-7.
3. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R,. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437: 436-9.
4. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schule R, Buettner R,. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-7.
5. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y,. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941-53.
6. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, Liang J, Sun L, Yang X, Shi L, Li R, Li Y, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009; 138: 660-72.
7. Schmidt DM, McCafferty DG,. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007; 46: 4408-16.
8. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R,. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006; 13: 563-7.
9. Yang M, Culhane JC, Szewczuk LM, Gocke CB, Brautigam CA, Tomchick DR, Machius M, Cole PA, Yu H,. Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat Struct Mol Biol 2007; 14: 535-9.
10. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM, Casero RA, Jr., Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 2007; 104: 8023-8.
11. Mimasu S, Umezawa N, Sato S, Higuchi T, Umehara T, Yokoyama S,. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 2010; 49: 6494-503.
12. Culhane JC, Wang D, Yen PM, Cole PA,. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J Am Chem Soc 2010; 132: 3164-76.
13. Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, Perkins B, Jones RJ, Woster PM, Casero RA, Jr., Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 2009; 15: 7217-28.
14. Koch MA, Wittenberg LO, Basu S, Jeyaraj DA, Gourzoulidou E, Reinecke K, Odermatt A, Waldmann H,. Compound library development guided by protein structure similarity clustering and natural product structure. Proc Natl Acad Sci USA 2004; 101: 16721-6.
15. Mimasu S, Sengoku T, Fukuzawa S, Umehara T, Yokoyama S,. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Biochem Biophys Res Commun 2008; 366: 15-22.
16. Holm L, Rosenstrom P,. Dali server: conservation mapping in 3D. Nucleic Acids Res 2010; 38: W545-9.
17. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, Muller JM, Greschik H, Kirfel J, Ji S, Kunowska N, Beisenherz-Huss C, et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature 2010; 464: 792-6.
18. Wetzel S, Wilk W, Chammaa S, Sperl B, Roth AG, Yektaoglu A, Renner S, Berg T, Arenz C, Giannis A, Oprea TI, Rauh D, et al. A scaffold-tree-merging strategy for prospective bioactivity annotation of gamma-pyrones. Angew Chem Int Ed Engl 2010; 49: 3666-70.
19. Magee JA, Chang LW, Stormo GD, Milbrandt J,. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 2006; 147: 590-8.
20. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, Kirfel J,. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010; 31: 512-20.